Pays: Canada
Langue: anglais
Source: Health Canada
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM)
VIIV HEALTHCARE ULC
J05AJ03
DOLUTEGRAVIR
25MG
TABLET
DOLUTEGRAVIR (DOLUTEGRAVIR SODIUM) 25MG
ORAL
30
Prescription
MISCELLANEOUS ANTIRETROVIRALS*
Active ingredient group (AIG) number: 0154870003; AHFS:
APPROVED
2017-02-03
_ _ _ _ _TIVICAY, dolutegravir _ _June 2023 _ _ _ _Page 1 of 51_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr TIVICAY dolutegravir tablets Tablets, 10, 25 and 50 mg dolutegravir (as dolutegravir sodium), oral dolutegravir dispersible tablets Dispersible tablets, 5 mg dolutegravir (as dolutegravir sodium), oral Antiretroviral Agent ViiV Healthcare ULC 75 Queen, Street Suite 1400 Montreal, Quebec Canada H3C 2N6 Date of Initial Authorization: NOV 08, 2013 Date of Revision: JUN 27, 2023 Submission Control Number: 272507 _©_ _2023 ViiV Healthcare group of companies or its licensor _ _Trademarks are owned by or licensed to the ViiV Healthcare group of companies_ _ _ _ _ _TIVICAY, dolutegravir _ _June 2023 _ _ _ _Page 2 of 51_ RECENT MAJOR LABEL CHANGES SECTION DATE 1 INDICATIONS 01/2021 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 01/2021 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage Adjustment 12/2021 7 WARNINGS AND PRECAUTIONS, General 01/2021 7 WARNINGS AND PRECAUTIONS, 7.1.3 Pediatrics 01/2021 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 10/2022 7 WARNINGS AND PRECAUTIONS, 7.1.2 Breast-feeding 10/2022 7 WARNINGS AND PRECAUTIONS, General 06/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ................................................................................................ 2 TABLE OF CONTENTS ................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ........................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics............................................................................................................ 4 1.2 Geriatrics .................................................................................. Lire le document complet